Molecular imaging of gastroenteropancreatic neuroendocrine tumors

Gastroenterology Clinics of North America

Volumn 39, Issue 4, 2010, Pages 923-935

  Miederer, Matthias ^a   Weber, Matthias M ^a   Fottner, Christian ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

111In octreotide scintigraphy; 123I MIBG scintigraphy; 18FDOPA PET; 68Ga DOTATOC PET; GEP NET; Molecular imaging; Neuroendocrine tumors

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; G PROTEIN COUPLED RECEPTOR; GALLIUM 68; INDIUM 111; IODINE 123; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M;

COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL LASER MICROSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG EXCRETION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOLOGY; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; HUMANS; MICROSCOPY, CONFOCAL; MOLECULAR IMAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN;

EID: 78549277478     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.08.031     Document Type: Review

References (50)

1. Ploeckinger U., Kloeppel G., Wiedenmann B., et al. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 2009, 90(4):349-363.
2. Klimstra D.S., Modlin I.R., Coppola D., et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010, 39(6):707-712.
3. Modlin I.M., Oberg K., Chung D.C., et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9(1):61-72.
4. Oberg K.E., Reubi J.C., Kwekkeboom D.J., et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010, 139(3):742-753.
5. Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?. Curr Opin Oncol 2010, 22(4):381-386.
6. Cimitan M., Buonadonna A., Cannizzaro R., et al. Somatostatin receptor scintigraphy versus chromogranin a assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003, 14(7):1135-1141.
7. Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20(8):716-731.
8. Kowalski J., Henze M., Schuhmacher J., et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003, 5(1):42-48.
9. Gabriel M., Decristoforo C., Kendler D., et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48(4):508-518.
10. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med 2006, 47(6):1059-1066.
11. Nikolaou A., Thomas D., Kampanellou C., et al. The value of 11C-5-hydroxy-tryptophan (5HTP) positron emission tomography (PET) in neuroendocrine tumour diagnosis and management: experience from one center. J Endocrinol Invest 2010, [Epub ahead of print]. PMID: 20332708.
12. Fottner C., Helisch A., Anlauf M., et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010, 95(6):2800-2810.
13. Christ E., Wild D., Forrer F., et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009, 94(11):4398-4405.
14. Mansi R., Wang X., Forrer F., et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009, 15(16):5240-5249.
15. Reubi J.C., Maecke H.R. Peptide-based probes for cancer imaging. J Nucl Med 2008, 49(11):1735-1738.
16. Zhang H., Chen J., Waldherr C., et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64(18):6707-6715.
17. Brogsitter C., Pinkert J., Bredow J., et al. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG. J Nucl Med 2005, 46(12):2112-2116.
18. Kratochwil C., Giesel F.L., Lopez-Benitez R., et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010, 16(10):2899-2905.
19. Reubi J.C., Schar J.C., Waser B., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000, 27(3):273-282.
20. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor scintigraphy in patients with carcinoid tumors. World J Surg 1996, 20(2):157-161.
21. de Herder W.W., Kwekkeboom D.J., Valkema R., et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005, 28(Suppl International 11):132-136.
22. Kwekkeboom D.J., Krenning E.P., Scheidhauer K., et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009, 90(2):184-189.
23. Koopmans K.P., Neels O.C., Kema I.P., et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008, 26(9):1489-1495.
24. Dromain C., de Baere T., Lumbroso J., et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005, 23(1):70-78.
25. Gibril F., Reynolds J.C., Chen C.C., et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999, 40(4):539-553.
26. Zhernosekov K.P., Filosofov D.V., Baum R.P., et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007, 48(10):1741-1748.
27. Schottelius M., Poethko T., Herz M., et al. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004, 10(11):3593-3606.
28. Miederer M., Seidl S., Buck A., et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009, 36(1):48-52.
29. Gabriel M., Oberauer A., Dobrozemsky G., et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009, 50(9):1427-1434.
30. Baum R.P., Prasad V., Hommann M., et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 2008, 170:225-242.
31. Goetz M., Kiesslich R. Advances of endomicroscopy for gastrointestinal physiology and diseases. Am J Physiol Gastrointest Liver Physiol 2010, 298(6):G797-G806.
32. Goetz M., Fottner C., Schirrmacher E., et al. In-vivo confocal real-time mini-microscopy in animal models of human inflammatory and neoplastic diseases. Endoscopy 2007, 39(4):350-356.
33. Kiesslich R., Goetz M., Neurath M.F. Confocal laser endomicroscopy for gastrointestinal diseases. Gastrointest Endosc Clin N Am 2008, 18(3):451-466. viii.
34. Fottner C., Mettler E., Goetz M., et al. In vivo molecular imaging of somatostatin receptors in pancreatic islet cells and neuroendocrine tumors by miniaturized confocal laser-scanning fluorescence microscopy. Endocrinology 2010, 151(5):2179-2188.
35. Rufini V., Calcagni M.L., Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 2006, 36(3):228-247.
36. Bombardieri E., Coliva A., Maccauro M., et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010, 54(1):3-15.
37. Havekes B., King K., Lai E.W., et al. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) 2010, 72(2):137-145.
38. Ilias L., Sahdev A., Reznek R.H., et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007, 14(3):587-599.
39. Ilias I., Chen C.C., Carrasquillo J.A., et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008, 49(10):1613-1619.
40. Hoegerle S., Altehoefer C., Ghanem N., et al. Whole-body 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 2001, 220(2):373-380.
41. Ahlstrom H., Eriksson B., Bergstrom M., et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995, 195(2):333-337.
42. Koopmans K.P., de Vries E.G., Kema I.P., et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006, 7(9):728-734.
43. Putzer D., Gabriel M., Kendler D., et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010, 54(1):68-75.
44. Haug A., Auernhammer C.J., Wangler B., et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009, 36(5):765-770.
45. Kayani I., Conry B.G., Groves A.M., et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009, 50(12):1927-1932.
46. Kruger S., Buck A.K., Blumstein N.M., et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med 2006, 260(6):545-550.
47. Binderup T., Knigge U., Loft A., et al. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010, 16(3):978-985.
48. Matsunari I., Aoki H., Nomura Y., et al. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction. Circ Cardiovasc Imaging 2010, 3(5):595-603.
49. Franzius C., Hermann K., Weckesser M., et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med 2006, 47(10):1635-1642.
50. Gotthardt M., Behe M.P., Grass J., et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006, 13(4):1203-1211.